# A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

> **NCT03622593** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 951 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Aflibercept
- **DRUG:** Faricimab
- **PROCEDURE:** Sham Procedure

## Key facts

- **NCT ID:** NCT03622593
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-09
- **Primary completion:** 2020-10-19
- **Final completion:** 2023-05-31
- **Target enrollment:** 951 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03622593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03622593, "A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03622593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*